Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101
- First four patient cohorts and dose levels have been completed and proved to be safe and well tolerated
- Enrollment for fifth cohort with a dose of 100 µg/kg has already started
- Patient from third cohort continues to be dosed and shows no progression of disease (stable disease)
Heidelberg Pharma AG announced today that the clinical Phase I/IIa study with the lead development candidate HDP-101 has already started to recruit patients for the fifth patient cohort with a dosing of 100 µg/kg. The Safety Review Committee’s (SRC) evaluation of patient data concluded that no dose-limiting toxicities have occurred to date. The first four dose levels have shown to be safe and well tolerated. So far 12 patients have been treated in the trial.